Sign up
Pharma Capital

PreveCeutical gets default judgement in part of civil claim

Preveceutical said it had received a default judgment against Essos Corporate Services Inc and Detona Capital
Law book
Preveceutical brought the action last year with the Supreme Court of British Columbia

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF), the health sciences firm, revealed it had prevailed so far in part of a previously reported civil claim.

The firm said that it had obtained a default judgement against Essos Corporate Services Inc. (Essos) and Detona Capital Corp. (Detona).

The firm brought the action to the Supreme Court of British Columbia late last year, against a group of defendants, including Essos and Detona, for various things, including fraudulent misrepresentation and breach of contract in connection with services that the defendants failed to provide to PreveCeutical.

READ: PreveCeutical Medical files civil claim against Bridgemark Group

Also, it covered various consulting agreements and subscription agreements entered into between PreveCeutical and certain of the defendants.

Default judgments are ordered when one party has failed to file and serve a response to the claim within the time allowed by the rules.

"The default judgement shows due process and that proceedings are moving forward. We have confidence in the judicial system and thank our shareholders for their continued patience while we see this through," said PreveCeutical's chairman and CEO, Stephen Van Deventer.

The defendants consist of Aly Babu Mawji, Justin Liu, BridgeMark Financial Corp., Rockshore Advisors Ltd. (formerly known as, Cam Paddock Enterprises Inc.), Detona Capital Corp., Escher Invest SA, Essos Corporate Services Inc., Jarman Capital Inc., JCN Capital Corp., Kendl Capital Limited, Lukor Capital, Northwest Marketing and Management Inc., Sway Capital Corp. and Tryton Financial Corp.

Damages and costs to be awarded to Preveceutical and against Essos and Detona are yet to be decided by the court.

The firm also noted it was continuing to pursue its claims against the other defendants.

Preveceutical did not immediately respond to a request for comment.

Essos Corporate Services Inc and Detona Capital Corp could not be reached for comment.

Contact Giles at [email protected]

Follow him on Twitter @Gile74

View full PREV profile View Profile
View All

Related Articles

Social media use
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.